Primary Health Properties said on 12 August 2025 that it has secured acceptances representing roughly 62.9% of Assura plc’s shares for its revised cash‑and‑share takeover proposal, a threshold that has allowed PHP to declare the offer wholly unconditional and push ahead with the acquisition process. According to the company’s regulatory announcement, all remaining conditions attached to the roughly $2.4 billion proposal have now been satisfied or waived and withdrawal rights have ceased, clearing the path for settlement and the admission of new PHP shares. The successful acceptance level marks a notable instance of investor support for a public‑market bid in a period otherwise dominated by private equity cash takeovers. (PHP said the revised offer was declared wholly unconditional on 12 August 2025.)

The RNS published by PHP sets out practical next steps: settlement timetables, CREST arrangements and procedures for payment and the admission of new PHP shares. It also details a small special dividend of 0.84p per Assura share, the closure of the Mix‑and‑Match facility and the mechanics by which PHP could move to cancel Assura’s London listing if it acquires 75% of issued shares. The announcement makes clear the transaction will proceed under the terms of the revised 0.38 new PHP shares plus 12.5p in cash per Assura share that PHP offered when it updated its approach. PHP’s statement frames the move as the next stage in an agreed transaction; independent observers will be watching whether further acceptances push the holding above the 75% threshold that would enable delisting.

Assura is a specialist owner and manager of GP and primary‑care sites across the UK. Company accounts for the year to 31 March 2025 show a portfolio of some 603 healthcare properties with a book value in the region of £3.1 billion, serving more than six million patients. Assura reported net rental income of £167.1 million, IFRS profit before tax of £166.0 million and EPRA earnings of £111.8 million for the year, with over 90% of rent roll deriving from general practitioners, NHS bodies and major healthcare providers—tenant covenants that underpinned investor interest in the proposed tie‑up. Assura’s board has consistently emphasised the company’s strategic role in primary‑care infrastructure as it weighed competing offers.

The takeover contest attracted an unusually public duel between PHP and US private equity firm KKR. Assura’s board backed PHP’s higher, mixed cash‑and‑shares proposal in June and has repeatedly urged shareholders to favour that offer, even as KKR lobbied for its rival all‑cash bid. KKR has argued that shifting market conditions had made its cash proposal relatively more attractive, and it continued to press its case with investors during the months‑long engagement. The intensity of the fight drew broader attention because of Assura’s exposure to the NHS and the wider policy implications of concentration in healthcare landlords.

PHP has disputed some of Assura’s earlier criticisms of its due diligence and matched KKR’s shareholder condition that the deal would require support from holders of more than 50% of voting rights. Industry coverage of PHP’s rebuttal noted the mechanics of the revised proposal—0.38 new PHP shares plus 12.5p cash per Assura share—and framed the argument from PHP’s camp as both a financial and strategic case for keeping Assura within the public markets. Andrew Saunders of Shore Capital, quoted by the Association of Investment Companies, argued the combination offers strategic merits and potential synergies for long‑term healthcare investment in the UK.

Regulatory scrutiny has been part of the backdrop. Competition authorities were reported to be considering whether to examine the proposed combination and, according to coverage of the process, an enforcement order relating to the transaction had been issued while the Competition and Markets Authority weighed next steps. The regulatory dimension underscores why bidders and the Assura board spent months testing investor sentiment and aligning legal and operational arrangements before moving to close the deal.

Market reaction to the acceptances has been broadly favourable among those who supported PHP. Analysts at Shore Capital described the outcome as “not only a victory for the company but also one for critical UK infrastructure, the UK stock market, the delivery of healthcare in the British Isles and society at large,” framing the result as a vote of confidence in continued public‑market ownership of strategic healthcare assets. Others have noted that the deal will be watched as a test case for whether listed infrastructure businesses can resist or accommodate private equity interest while preserving public‑market liquidity.

With the revised offer now wholly unconditional, attention will turn to the pace at which remaining holders tender their shares and to the timetable for settlement and share admissions laid out in PHP’s announcement. If acceptances reach the 75% threshold, PHP has the contractual option to squeeze out remaining minority holders and cancel Assura’s listing—an outcome that would mark the culmination of a contest that has highlighted competing investor views on the best ownership model for NHS‑serving property. For patients, policymakers and institutional investors alike, the transaction underscores the intersection of capital markets, infrastructure policy and the delivery of healthcare services.

📌 Reference Map:

Source: Noah Wire Services